AR065812A1 - Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto - Google Patents

Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto

Info

Publication number
AR065812A1
AR065812A1 ARP080101181A ARP080101181A AR065812A1 AR 065812 A1 AR065812 A1 AR 065812A1 AR P080101181 A ARP080101181 A AR P080101181A AR P080101181 A ARP080101181 A AR P080101181A AR 065812 A1 AR065812 A1 AR 065812A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
nhc
optionally substituted
hydroxyl
Prior art date
Application number
ARP080101181A
Other languages
English (en)
Inventor
J Kaplan
Derek Cecil Cole
Matthew Gregory Bursavich
J Verheijen
D J Richard
M Lefever
Pawel Wojciech Nowak
A Zask
K J Curran
D Malwitz
S Ayral-Kaloustian
K Yu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR065812A1 publication Critical patent/AR065812A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Análogo de pirazolopirimidina utilizables como inhibidores de cinasa mTOR y cinasa PI3, métodos para elaborar los análogos de pirazolopirimidina, composiciones que comprenden un análogo de pirazolopirimidina y métodos para tratar trastornosrelacionados con mTOR que comprende administrar a un sujeto en necesidad de este una cantidad efectiva de un análogo de pirazolopirimidina así como el tratamiento de trastornos relacionados PI3K que comprende administrar una cantidad efectiva de unanálogo de pirazolopirimidina a un sujeto. util para el cáncer, aterosclerosis, artritis, psoriasis, rinon. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable o tautomero de estos, en donde: R1, es como enformula (2), X5, es -O-, -CH2-O-, o -S(O)n-, y uno cualquiera o más de los átomos de hidrogeno en el anillo de R1 se pueden reemplazar independientemente con alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-3, acilo C1-3, alcoxicarbonilo C1-3, amino(alquilo C1-6), hidroxilo, fluor, o -CN, en donde cualquiera de los dos átomos de hidrogeno adherido al mismo átomo de carbono de R1 se pueden reemplazar por un átomo de oxígeno, formando un carbonilo (C=O); n es un entero de 0 a 2; R2 es a)arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: b) (i) halogeno, (ii) alquilo C1-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, heterociclo, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iii) alcoxi C1-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iv) alcoxicarbonilo C1-6, (v) alquenilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquiloC1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vi) alquinilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de halogeno, -NH2, - NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquiloC1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquiloC3-8, (vii) cicloalquilo C3-8 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, -O-alquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquiloC1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, carboxiamidoalquil- y -NO2, (viii) arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquiloC1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (ix) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (x) perfluoroalquilo C1-6-, (xi) hidroxilo, (xii) NR16R17, (xiii) NO2, (xiv) CN, (xv)CO2H, (xvi) CF3, (xvii) CF3O, (xviii) alquiltio C1-6, (xix) -SO2NR16R17, (xx) -O-C(O)NR16R17, (xxi) -C(O)NR16R17, (xxii) NR17C(O)R16, (xxiii) N(alquilo C1-6)C(O)R16, (xxiv) -NHC(O)NR16R17, (xxv) -NHC(O)NHNR16R17, (xxvi) -NHC(O)OR18, (xxvii) -NHC(O)NHOR16, (xxviii) -NH(SO2)NH-(alquilo C1-6), (xxix) -NH(SO2)-(alquilo C1-6), (xxx) -NH(SO2)NH-arilo C6-14, (xxxi) -NHC(S)-NH-alquilo C1-6, (xxxii) -N=C(S-alquilo C1-6)(NH-alquilo C1-6), (xxxiii) -S(O)p-arilo C6-14, (xxxiv) -S(O)p-heteroarilo C1-9, (xxxv) -N(H)-C(=N-(CN))-(NR16R17), y (xxxvi) -N(H)-C(=N-(CN))(O-R16), c) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: (i) halogeno, (ii) alquilo C1-6 opcionalmente sustituido con de 1a 3 sustituyentes independientemente seleccionados de halogeno. -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-5, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iii) alcoxi C1-6 opcionalmente sustituido con de 1 a 3 sustituyentesindependientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN,hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (iv) alcoxicarbonilo C1-6, (v) alquenilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentesindependientemente seleccionados de halogeno, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN,hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vi) alquinilo C2-6 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados dehalogeno, -NH2, - NH(alquilo C1-6), -N(alquilo C1-6)(alquilo C1-6), -N(alquilo C1-3)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHC(O)H, -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)(alquilo C1-6), -CN, hidroxilo, alcoxi C1-6, alquilo C1-6, -C(O)OH, -C(O)O(alquilo C1-6), -C(O)(alquilo C1-6), arilo C6-14, heteroarilo C1-9, y cicloalquilo C3-8, (vii) cicloalquilo C3-8 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquiloC1-6)-, hidroxilo, -O-alquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, carboxiamidoalquil- y -NO2, (viii) arilo C6-14opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo, halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-, y -NO2, (ix) heteroarilo C1-9 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de alquilo C1-6, halo,halo(alquilo C1-6)-, hidroxilo, hidroxialquilo C1-6, -NH2, amino(alquilo C1-6)-, (alquilo C1-6)amino-, di(alquilo C1-6)amino-, -COOH, -C(O)O-(alquilo C1-6), -OC(O)-(alquilo C1-6), (alquilo C1-6)carboxiamido-, -C(O)NH2, (alquilo C1-6)N-alquilamido-,y -NO2, (x) perfluoroalquilo C1-6-, (xi) hidroxilo, (xii) NR16R17, (xiii) NO2, (xiv) CN, (xv) CO2H, (xvi) CF3, (xvii) CF3O, (xviii) alquiltio C1-6, (xix) -SO2NR16R17,(xx) -C(O)NR16R17, (xxi) NR17C(O)R16, (xxii) -NHC(O)NR16R17, (xxiii) -NHC(O)NHNR16R17, (xxiv) -NHC(O)OR18, (xxv) -NHC(O)NHOR16, (xxvi) -NH(SO2)NH-alquilo C1-6, (xxvii) -NH(SO2)NH-arilo C6-14, (xxviii) -NHC(S)-NH-alquilo C1-6, (xxix) -N=C(S-alquilo C1-6)(NH-alquilo C1-6), (xxx) -S(O)p-arilo C6-14, (xxxi) -S(O)p-heteroarilo C1-9, (xxxii) -N(H)-C(N-(CN))-(NR16R17), (xxxiii) -N(H)-C(N-(CN))-(O-R16), y (xxxiv) -N(H)-C(=N-(CN))-(O-arilo C6-14); d) -HC=CH-arilo C6-14; e) heterociclo adherido al átomo de carbono en el anillo del heterociclo; f) o -HC=CH-heteroarilo C1-9; R16 y R17 son cada uno independientemente a) H; b) alcoxi C1-6 c) perfluoroalquilo C1-6, d) arilo C6-14 opcionalmente sustituido con de 1 a 3 sustituyentes independientemente seleccionados de: (i) alquilo C1-6 en donde el alquiloC1-6 se sustituye opcionalmente con uno o más sustituyentes independientemente seleccionados de: A) heterociclo opcionalmente sustituido con alquilo C1-6, B) NH2-, C) (alquilo C1-6)amino-, y D) di(alquilo C1-6)amino-, (ii) alcoxi C1-6, (iii) halo,(iv) halo(alquilo C1-6)-, (v) hidroxilo, (vi) hidroxialquilo C1-6, (vii) heterociclo opcionalmente sustituido con alquilo C1-6, (viii) NH2, (ix) amino(alquilo C1-6)-, (x) (alquilo C1-6)amino-, (xi) di(alquilo C1-6)amino-, (xii) alcoxi C1-6-alquilenoC1-6-NH-alquileno C1-6-, (xiii) hidroxialquilo C1-6-NH-alquileno C1-6-, (xiv) amino(alquilo C1-6)-NH-alquileno C1-6-, (xv) di(alquilo C1-6)amino-alquileno C1-6-NH-alquiIeno C1-6-, (xvi) hidroxialquilo C1-6-NH-, (xvii) amino(alquilo C1-6)-NH-,(xviii) -COOH, (xix) -C(O)O-(alquilo C1-6), (xx) -OC(O)-(alquilo C1-4), (xxi) (alquilo C1-6)carboxiamido-, (xxii) -C(O)NH2, (xxiii) (alquilo C1-6)N-alquilamido-, (xxiv) alc
ARP080101181A 2007-03-21 2008-03-19 Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto AR065812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91930107P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR065812A1 true AR065812A1 (es) 2009-07-01

Family

ID=39766744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101181A AR065812A1 (es) 2007-03-21 2008-03-19 Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto

Country Status (13)

Country Link
US (1) US20080234262A1 (es)
EP (1) EP2078021A2 (es)
JP (1) JP2010522195A (es)
CN (1) CN101675051A (es)
AR (1) AR065812A1 (es)
AU (1) AU2008228964A1 (es)
BR (1) BRPI0809239A2 (es)
CA (1) CA2681501A1 (es)
CL (1) CL2008000815A1 (es)
MX (1) MX2009010132A (es)
PE (1) PE20081888A1 (es)
TW (1) TW200900404A (es)
WO (1) WO2008115974A2 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516743A (ja) * 1996-09-04 2000-12-12 インタートラスト テクノロージーズ コーポレイション 信用インフラストラクチャストラクチャ支援システム、安全な電子交易、電子商取引、交易プロセス制御及び自動化のための方法及び技術、分散コンピューテーション及び権利管理
KR20100042280A (ko) * 2007-07-09 2010-04-23 아스트라제네카 아베 Ｍｔｏｒ 키나제 및/또는 ｐｉ３ｋ와 연관된 질환에 사용되는 모르폴리노 피리미딘 유도체
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
AU2009233951B2 (en) 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2010014939A1 (en) * 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PL2350075T3 (pl) 2008-09-22 2014-07-31 Array Biopharma Inc Podstawione związki imidazo[1,2b]pirydazynowe jako inhibitory kinaz Trk
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
BRPI0919873B8 (pt) 2008-10-22 2021-05-25 Array Biopharma Inc compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
JP5877064B2 (ja) * 2008-11-11 2016-03-02 エックスカバリー ホールディング カンパニー エルエルシー ＰＩ３Ｋ／ｍＴＯＲキナーゼ阻害剤
WO2010103094A1 (en) 2009-03-13 2010-09-16 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
WO2010129622A1 (en) * 2009-05-04 2010-11-11 Macusight, Inc. Mtor pathway inhibitors for treating ocular disorders
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
WO2011002887A1 (en) * 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SG178454A1 (en) * 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
NZ598808A (en) * 2009-09-09 2014-07-25 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
CA2780018C (en) * 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
CA2788678C (en) 2010-02-03 2019-02-26 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2011107585A1 (en) 2010-03-04 2011-09-09 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US8912178B2 (en) * 2010-05-19 2014-12-16 Xcovery Holdings Company, LLC mTOR selective kinase inhibitors
LT3205654T (lt) 2010-05-20 2019-05-27 Array Biopharma, Inc. Makrocikliniai junginiai kaip trk kinazės slopikliai
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2830516C (en) 2011-03-23 2017-01-24 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
JP2014510122A (ja) 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
CN103130793B (zh) * 2011-11-30 2016-09-21 中国人民解放军军事医学科学院毒物药物研究所 3-(1-芳基哌啶-4-基)-2-芳基噻唑啉-4-酮类化合物、其制备方法及用途
RU2014149145A (ru) 2012-05-23 2016-07-20 Ф. Хоффманн-Ля Рош Аг Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
JP2015518870A (ja) * 2012-06-07 2015-07-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾロピリミドン及びタンキラーゼのピラゾロピリドン阻害剤
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
EP2970186B1 (en) * 2013-03-15 2020-06-10 Dow AgroSciences LLC 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic) pyrimidine-4-carboxylates and their use as herbicides
US9637505B2 (en) 2013-03-15 2017-05-02 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
MY184855A (en) 2013-03-15 2021-04-27 Dow Agrosciences Llc 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
MX2015014590A (es) 2013-04-17 2016-03-03 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
BR112015026238A8 (pt) 2013-04-17 2019-12-24 Signal Pharm Llc composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
SG11201607586UA (en) * 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
TWI698178B (zh) 2014-09-15 2020-07-11 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與光系統ii抑制劑的協同性雜草控制
TWI689251B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與合成生長素除草劑及/或生長素轉運抑制劑的協同性雜草控制
TWI689252B (zh) 2014-09-15 2020-04-01 美商陶氏農業科學公司 源自於施用吡啶羧酸除草劑與乙醯乳酸合成酶（ａｌｓ）抑制劑的協同性雜草控制
TWI694770B (zh) 2014-09-15 2020-06-01 美商陶氏農業科學公司 包含吡啶羧酸除草劑之安全的除草組成物（二）
TWI685302B (zh) 2014-09-15 2020-02-21 美商陶氏農業科學公司 包含吡啶羧酸除草劑之安全的除草組成物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PL3699181T3 (pl) 2014-11-16 2023-05-22 Array Biopharma, Inc. Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
KR102016822B1 (ko) * 2014-12-17 2019-08-30 화이자 인코포레이티드 정맥내 투여용 pi3k/mtor-억제제의 제형
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
GEP20227339B (en) 2016-04-04 2022-01-25 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)- pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydro-xypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3024603A1 (en) 2016-05-18 2017-11-23 Charles Todd Eary Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7348071B2 (ja) 2017-05-02 2023-09-20 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤としてのラパマイシン類似体
CN117860758A (zh) 2017-05-23 2024-04-12 梅制药公司 联合疗法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20200019229A (ko) 2017-06-22 2020-02-21 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
US11351176B2 (en) 2017-08-14 2022-06-07 Mei Pharma, Inc. Combination therapy
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
CN110833551B (zh) * 2018-08-15 2023-03-24 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗急性胰腺炎的用途
CN110950868B (zh) * 2018-09-27 2022-05-13 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3800188A1 (en) * 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022106579A1 (en) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for treating a disease associated with macrophage senescence
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CA3207998A1 (en) 2021-02-16 2022-08-25 Geoffrey M. Lynn Self-assembling nanoparticles based on amphiphilic peptides
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022268025A1 (zh) * 2021-06-22 2022-12-29 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115304600B (zh) * 2022-09-29 2023-01-13 北京鑫开元医药科技有限公司 mTOR抑制剂、制备方法及用途
US20240269269A1 (en) 2022-10-25 2024-08-15 Vaccitech North America, Inc. Self-Assembling Nanoparticles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847908A (en) * 1973-03-05 1974-11-12 Squibb & Sons Inc 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines
CA2599320A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DK2004654T3 (da) * 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister

Also Published As

Publication number Publication date
CA2681501A1 (en) 2008-09-25
AU2008228964A8 (en) 2009-11-19
TW200900404A (en) 2009-01-01
BRPI0809239A2 (pt) 2014-11-25
AU2008228964A1 (en) 2008-09-25
CN101675051A (zh) 2010-03-17
MX2009010132A (es) 2009-10-12
EP2078021A2 (en) 2009-07-15
WO2008115974A2 (en) 2008-09-25
PE20081888A1 (es) 2008-12-20
CL2008000815A1 (es) 2008-05-30
JP2010522195A (ja) 2010-07-01
US20080234262A1 (en) 2008-09-25
WO2008115974A3 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
AR065812A1 (es) Compuesto, composicion farmaceutica y metodos para tratar un trastorno relacionados con pi3k o con mtor, y proceso para sintetizar el compuesto
PE20071182A1 (es) Derivados de bencimidazol sustituidos con cromano como inhibidores de la bomba de acido
NZ719592A (en) Pyrrolo[2,1-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
AR084001A1 (es) Monobactamas y su uso en el tratamiento de infecciones bacterianas
AR072508A1 (es) Inhibidores alfa 7 nicotinicos del receptor de acetilcolina
PE20070335A1 (es) Benzimidazoles sustituidos y metodos para su preparacion
AR077239A1 (es) Prodrogas de compuestos n-acidicos utiles en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y trastorno bipolar.
ME01111B (me) Triazinska jedinjenja kao inhibitori p13 kinaze i mtor
TW200614992A (en) Combinations for the treatment of diseases involving cell proliferation
MX2008002163A (es) Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades oseas.
MX2007005679A (es) Metodo para tratamiento de desordenes de movimiento.
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
ECSP088762A (es) Tratamiento del dolor
AR051889A1 (es) Sulfonas de tripeptido y tetrapeptido
UY31065A1 (es) Heterociclos ciclicos
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
TW200639159A (en) Treatment of pain
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
RU2013146659A (ru) Способы лечения рака
JP2007500707A5 (es)
RU2014133744A (ru) Соединения и способы лечения кандидоза и инфекций aspergillus
AR058398A1 (es) Diazepinonas, procesos de obtencion , composiciones farmaceuticas y su uso como inhibidores de quinasas.
AR055271A1 (es) Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
HK1156019A1 (en) (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine (-)- 26-
RU2430917C2 (ru) Бициклические производные в качестве ингибиторов сетр

Legal Events

Date Code Title Description
FB Suspension of granting procedure